Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

H02 combined with CHOP regimen and rituximab injection (Rituximab) combined with CHOP regimen in the treatment of newly treated diffuse large B-cell lymphoma.

  • 0 views
  • 16 Sep, 2021
  • 1 location
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk, Non-mass Diffuse Large B-cell Lymphoma: a Multi-center, Prospective, Randomized Controlled Study

  • 0 views
  • 29 Apr, 2022
  • 1 location
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)

lenalidomide
vincristine
cyclophosphamide
anaplastic large cell lymphoma
neutrophil count
  • 0 views
  • 24 Jul, 2021
  • 1 location
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

This is a prospective single-arm phase II study, and the purpose of this study is to evaluate the efficiency of zanubrutinib combined with R-CHOP regimen in newly diagnosed primary intraocular

  • 0 views
  • 04 Jun, 2021
  • 1 location
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

compared to R-CHOP regimen in this cohort of patients. The investigators therefore design this phase I/II study to investigate the safety and efficacy of lenalidomide in combination with R-DA EPOCH in

da-epoch
lenalidomide
etoposide
vincristine
rituximab
  • 0 views
  • 25 Jan, 2021
  • 1 location
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Phase I portion of this study will evaluate the efficacy and saftey of toripalimab plus rituximab in treating untreated elderly diffuse large B cell lymphoma patients. The aim of phase II portion of this study will evaluate the efficacy and saftey of toripalimab plus rituximab followed by R-CHOP(rituximab, cyclophosphamide, doxorubicin, …

colony stimulating factor
cancer chemotherapy
rituximab
ct scan
vincristine
  • 1 views
  • 30 Apr, 2022
  • 1 location
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

measurable disease
peripheral t-cell lymphoma
chidamide
t-cell lymphoma
  • 0 views
  • 30 Apr, 2022
  • 1 location
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL

This study is a Randomized Phase II Study to Compare Efficacy of CHOP versus Fractionated ICED in Transplant-eligible Patients with Previously Untreated Peripheral T-cell Lymphoma.

enteropathy
intestinal t-cell lymphoma
etoposide
panniculitis
angioimmunoblastic t-cell lymphoma
  • 10 views
  • 26 Jan, 2021
  • 1 location
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

This prospective,multi-center,open-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral T-cell lymphoma.

lenalidomide
vincristine
cyclophosphamide
t-cell lymphoma
doxorubicin
  • 0 views
  • 01 May, 2022
  • 1 location
Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL

Central nervous system (CNS) relapse is a devastating event of diffuse large B cell lymphoma (DLBCL). It occurs in 4%-7% of DLBCL in general and the rate is considerably higher in high-risk patients, resulting in a poor outcome.Effective methods of CNS prophylaxis have not yet been developed. Evidence for intrathecal …

  • 0 views
  • 30 Sep, 2021
  • 1 location